...
首页> 外文期刊>Journal of neurosurgical sciences >Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme
【24h】

Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme

机译:肿瘤渗透CD63阳性细胞对胶质母细胞瘤多形患者存活的影响

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer in adults. It is suggested that tumour microenvironment might influence treatment outcome. The aim of the study was to evaluate the impact of tumor infiltrating CD63 positive (CD63+) inflammatory and immune cells on treatment response and survival of GBM patients.METHODS: Forty patients were operated and received postoperative radiotherapy (±chemotherapy for recurrent disease). In surgically excised GBM tissues, the number of CD63+ cells per microscopic field was determined and correlated with patient's survival.RESULTS: Immunohistochemical parameters were examined by two independent researchers whose results were in good accordance (R=0.8, P<0.001). Median survival time of the study group was 10.0 months (95% Cl 9.0-11.0). However, the survival time clearly depended on the number of CD63+ cells in GBM tissue (log rank test, P=0.003). Median survival times for patients with low (
机译:背景:胶质母细胞瘤多形形(GBM)是成人中最具侵略性的脑癌。建议肿瘤微环境可能影响治疗结果。该研究的目的是评估肿瘤浸润的CD63阳性(CD63 +)炎症和免疫细胞对GBM患者治疗反应和存活的影响。方法:进行40例患者并接受术后放疗(±复发性疾病化疗)。在手术切除的GBM组织中,确定每显微静脉场的CD63 +细胞数与患者的存活率相关。结果:由两个独立的研究人员检查免疫组化参数,其结果良好(R = 0.8,P <0.001)。研究组的中位生存时间为10.0个月(95%Cl.9.0-11.0)。然而,存活时间清楚地依赖于GBM组织中的CD63 +细胞数量(对数级测试,P = 0.003)。低(<中位数)和高(≥MEDIAN)CD63 +细胞数量的患者的中位存活时间分别为90个月(95%CL 8.1-9.9)和12.0个月(95%CL.8.5.5)。在多变量分析中,作为整体存活的显着独立预测器的CD63 +细胞的数量(HR 2.4,95%Cl 1.2-5.1,P = 0.02)。结论:GBM组织中肿瘤肿瘤的肿瘤数量较多的肿瘤浸润和免疫细胞术后放疗后更好的存活率相对应。由于放射疗法是GBM中佐剂治疗的基石之一,因此需要进一步研究以更好地了解GBM生物学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号